Atomoxetine-hydrochloride-Tomoxetine-hydrochloride-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAtomoxetine hydrochlorideCat. No.: HY-17385CAS No.: 82248-59-7Synonyms: Tomoxetine hydrochloride; LY 139603; (R)-Tomoxetinehydrochloride分式: CHClNO分量: 291.82作靶点: Others作通路: Others储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C

2、6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (342.68 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.4268 mL 17.1338 mL 34.2677 mL5 mM 0.6854 mL 3.4268 mL 6.8535 mL10 mM 0.3427 mL 1.7134 mL 3.4268 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据

3、您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (8.57 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)1/2 Master of Small Molecule

4、s 您边的抑制剂师www.MedChemESolubility: 2.5 mg/mL (8.57 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (8.57 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Atomoxetine hydrochloride去甲肾上腺素重 吸收抑制剂，与NET，SERT和DAT的放射性配体结合的Ki分别为5，77和1451 nM。户使本产品发表的科研献 School of Pharmacy & Pharmaceutical

5、Sciences Trinity College Institute of Neuroscience Trinity College, University of Dublin.2019 Mar.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine orsti

6、mulant medications. Pharmacoepidemiol Drug Saf. 2012 Dec 26.2. Turner M, Wilding E, Cassidy E, Dommett EJ. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneouslyhypertensive rat. Behav Brain Res. 2012 Dec 22;243C:28-37.3. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetin

7、e increases extracellular levels of norepinephrine and dopamine in prefrontalcortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711.4. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and theirmetabolites. J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22.5. AtomoxetineMcePdfHeightCaution: Product has not been fully validated for medical applications.For rese